MURA
Income statement / Annual
Last year (2023), Mural Oncology plc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Mural Oncology plc's net income was -$207.45 M.
See Mural Oncology plc’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$2.57 M |
$1.54 M |
$1.47 M |
| Gross Profit |
-$2.57 M |
-$1.54 M |
-$1.47 M |
| Gross Profit Ratio |
0 |
0 |
0 |
| Research and Development
Expenses |
$162.03 M
|
$170.07 M
|
$159.82 M
|
| General & Administrative
Expenses |
$30.71 M
|
$25.08 M
|
$15.55 M
|
| Selling & Marketing
Expenses |
-$667,000.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$30.04 M
|
$25.08 M
|
$15.55 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$192.07 M |
$195.15 M |
$175.37 M |
| Cost And Expenses |
$194.64 M |
$195.15 M |
$175.37 M |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$2.57 M
|
$1.54 M
|
$1.47 M
|
| EBITDA |
-$192.72 M
|
-$183.38 M
|
-$173.89 M
|
| EBITDA Ratio |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$649,000.00
|
$10.22 M
|
$0.00
|
| Income Before Tax |
-$195.29 M |
-$195.15 M |
-$175.37 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
| Income Tax Expense |
$12.16 M |
$4.88 M |
$68,000.00 |
| Net Income |
-$207.45 M |
-$200.03 M |
-$175.43 M |
| Net Income Ratio |
0 |
0 |
0 |
| EPS |
-12.43 |
-11.99 |
-10.51 |
| EPS Diluted |
-12.43 |
-11.99 |
-10.51 |
| Weighted Average Shares
Out |
$16.69 M
|
$16.69 M
|
$16.69 M
|
| Weighted Average Shares
Out Diluted |
$16.69 M
|
$16.69 M
|
$16.69 M
|
| Link |
|
|
|
